Table 1. Preoperative clinical characteristics and body compositions of 160 HCC patients with comparison between sarcopenic and nonsarcopenic group.
| Variable | Total (n=160) | Sarcopenic group (n=28, 17.5%) | Nonsarcopenic group (n=132, 82.5%) | P value |
|---|---|---|---|---|
| Age (year) | 55.19±11.49 | 64.07±8.32 | 53.31±11.22 | <0.001 |
| Male sex, no (%) | 120 (75.0) | 17 (60.7) | 103 (78.0) | 0.055 |
| BMI (kg/m2) | 24.26±2.80 | 23.57±2.79 | 24.42±2.81 | 0.079 |
| Alcohol intake, no (%) | 76 (47.5) | 11 (39.3) | 65 (49.2) | 0.338 |
| Smoking, no (%) | 64 (40.0) | 9 (32.1) | 55 (41.7) | 0.350 |
| HBV/HCV/non-viral, no (%) | 125 (78.1)/12 (7.5)/23 (14.4) | 18 (64.0)/1 (4.0)/9 (32.0) | 107 (91.0)/11 (8.0)/14 (11.0) | 0.003 |
| DM, no (%) | 27 (16.9) | 5 (17.9) | 22 (16.7) | 0.879 |
| Platelet (103/μL) | 160 (117–199) | 163 (117–216) | 158 (118–198) | 0.998 |
| Albumin (g/dL) | 4.15 (3.83–4.40) | 4.10 (3.73–4.38) | 4.2 (3.9–4.4) | 0.577 |
| Prothrombin time (INR) | 1.09 (1.03–1.16) | 1.11 (1.01–1.18) | 1.09 (1.03–1.15) | 0.047 |
| ALT (IU/L) | 32.5 (21.0–52.0) | 26.5 (16.3–37.3) | 35.5 (22–55.5) | 0.001 |
| ALP (IU/L) | 81.5 (64.0–104.0) | 93.5 (79.5–119) | 80.0 (62.3–100.8) | 0.093 |
| Cr (mg/dL) | 0.92 (0.08–1.02) | 0.90 (0.73–1.10) | 0.93 (0.80–1.02) | 0.295 |
| Cirrhosis*, no (%) | 86 (53.8) | 16 (57.1) | 70 (53.0) | 0.692 |
| Child-Pugh class, A/B, no (%) | 154 (96.3)/6 (3.7) | 27 (96.4)/1 (3.6) | 127 (96.2)/5 (3.8) | 0.956 |
| MELD-Na score | 8 [7–9] | 8 [7–9] | 8 [7–9] | 0.786 |
| AFP (ng/mL) | 19.5 (4.2–432.0) | 13.60 (1.50–3120.00) | 26.0 (4.8–428.8) | 0.965 |
| Tumor number | 1 [1–1] | 1 [1–1] | 1 [1–1] | 0.331 |
| Single tumor, no (%) | 142 (88.8) | 24 (85.7) | 118 (89.4) | 0.612 |
| Tumor size (cm) | 3.3 (2.4–5.0) | 3.9 (2.61–6.4) | 3.3 (2.4–5.0) | 0.331 |
| BCLC stage, 0/A/B/C, no (%) | 11 (6.9)/107 (66.9)/31 (19.4)/11 (6.9) | 1 (3.6)/20 (71.4)/5 (17.9)/2 (7.1) | 10 (7.6)/87 (65.9)/26 (19.7)/9 (6.8) | 0.844 |
| TNM stage, I/II/III/IV, no (%) | 75 (46.9)/62 (38.8)/23 (14.4)/0 | 12 (42.9)/12 (42.9)/4 (14.3)/0 | 63 (47.7)/50 (37.9)/19 (14.4)/0 | 0.749 |
| Death, no (%) | 72 (45.0) | 20 (71.4) | 52 (39.4) | 0.003 |
| Recurrence, no (%) | 89 (55.6) | 16 (57.1) | 73 (55.3) | 0.217 |
*, cirrhosis was pathologically confirmed. HCC, hepatocellular carcinoma; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; DM, diabetes mellitus; INR, international normalized ratio; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Cr, creatinine; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; TNM, tumor-node-metastasis.